Status:
COMPLETED
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
Lead Sponsor:
Odense University Hospital
Conditions:
Acromegaly
Eligibility:
All Genders
22-72 years
Phase:
PHASE4
Brief Summary
The morbidity and the mortality in acromegalic patients closely correspond to growth hormone (GH) levels and therefore efficient long-term treatment is important. Neurosurgery is the first choice of ...
Detailed Description
Introduction The morbidity and the mortality in acromegalic patients closely correspond to growth hormone (GH) levels and therefore efficient long-term treatment is important (1). Neurosurgery is the...
Eligibility Criteria
Inclusion
- All the patients which receive octreotide LAR can be included;
- New diagnosed patients with clinical and biochemical acromegaly , if medicine therapy is indicated;
- As long as they do not fit in the exclusion criteria.
Exclusion
- Which had not given their consent after they received standard information about the study;
- Current malign disease;
- Somatostatin analogues intolerance;
- Elevation of lever enzymes;
- Pregnancy.
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00145405
Start Date
September 1 2002
End Date
December 1 2004
Last Update
September 8 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, Odense University Hospital
Odense, Funen, Denmark, 5000